Advertisement

Agios Pharmaceuticals Inc., a Cambridge biotech focused on cancer metabolism-based therapeutics, has named Scott Biller as chief scientific officer.

Biller worked previously as vice president and head of global discovery chemistry at the Novartis Institutes for BioMedical Research (NIBR), where he oversaw the research metabolism and pharmacokinetics groups, in addition to medicinal, combinatorial and computational chemistry. Before joining Novartis in 2003, Biller served as vice president, pharmaceutical candidate optimization, at the Bristol Myers Squibb Pharmaceutical Research Institute and executive director of drug discovery chemistry for the BMS research site in Lawrenceville, N.J.

SOURCE

Advertisement
Advertisement